

Name of Journal: *World Journal of Clinical Oncology*

Manuscript NO: 55011

Manuscript Type: MINIREVIEWS

Predictive indicators of successful TKI discontinuation in patients with chronic myeloid leukemia

Predicting successful TKI discontinuation in CML

Ruth Stuckey, Juan Francisco López Rodríguez, Santiago Sánchez Sosa, Adrián Segura Díaz, Nuria Sánchez Farías, Cristina Bilbao Sieyro, María Teresa Gomez-Casares

Match Overview

1	Crossref 77 words Delphine Rea, Jean-Michel Cayuela. "Treatment-free re... ssion in patients with chronic myeloid leukemia", Internati	2%
2	Crossref 64 words Mario Annunziata, Massimiliano Bonifacio, Massimo Brec cia, Fausto Castagnetti et al. "Current Strategies and Futu	1%
3	Crossref 57 words Aisling Nee, Jeffrey H. Lipton. "Update on the managem... nt of chronic myeloid leukemia: current best practice and f	1%
4	Crossref 41 words Juan Carlos Hernández-Boluda, Arturo Pereira, Irene Pas tor-Galán, Alberto Alvarez-Larrán et al. "Feasibility of treat	1%
5	Crossref 40 words "Neoplastic Diseases of the Blood", Springer Science and Business Media LLC, 2018	1%
6	Crossref 37 words Giuseppe Saglio, Giora Sharf, Antonio Almeida, Andrija B ogdanovic et al. "Considerations for Treatment-free Remi	1%



国内版

国际版

Predictive indicators of successful TKI discontinuation in patients with ch



Chat with Bing



Sign in



Microsoft Bing

ALL

IMAGES

VIDEOS

59,900 Results

Any time ▼

Tyrosine kinase inhibitor discontinuation in patients with ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318861>

Jan 03, 2019 · Introduction. The introduction of imatinib, a selective tyrosine kinase inhibitor (**TKI**), revolutionized the treatment of **chronic myeloid leukemia** (CML) and changed the natural history of the disease [1, 2]. Subsequently, four additional TKIs were approved for the treatment of CML: bosutinib, dasatinib, nilotinib, and ponatinib.

Cited by: 17

Author: Kamal Chamoun, Hagop Kantarjian, Ram...

Publish Year: 2019

Discontinuation of Tyrosine Kinase Inhibitors in Chronic ...

<https://www.frontiersin.org/articles/10.3389/fonc.2019.00372/full> ▼

May 14, 2019 · This **meta-analysis** of observational studies of **CML patients** with **stable DMR** to **TKIs** focused on efficacy and safety of **TKI discontinuation** but also exploring the factors contributing to **successful TFR**. Estimated loss of **MMR** was 16, 34, 39, and 41% at 3, 6, 12, and 24 months, respectively, for **patients** who **discontinued TKI treatment**.

Search Tools

Turn off Hover Translation (关闭取词)



ALL

IMAGES

VIDEOS



Add the Give with Bing extension >

31,300 Results

Any time ▾

[Discontinuation of tyrosine kinase inhibitors in chronic ...](#)

<https://www.ncbi.nlm.nih.gov/pubmed/25591583>

Discontinuation of tyrosine kinase inhibitors in **chronic myeloid leukemia** patients - worldwide battlefield. Dvorak P, Lysak D, Vokurka S. Advances in understanding the pathogenesis of **chronic myeloid leukemia** (CML) and implementation of the therapy with tyrosine kinase inhibitors (TKI) could be considered as a prototype of **successful** fight ...

Cited by: 2

Author: Dvorak P, Lysak D, Vokurka S

Publish Year: 2015

[Discontinuation of Tyrosine Kinase Inhibitors in Chronic ...](#)

<https://www.frontiersin.org/articles/10.3389/fonc.2019.00372/full> ▾

May 14, 2019 · This **meta-analysis** of observational studies of **CML patients** with **stable DMR** to **TKIs** focused on efficacy and safety of **TKI discontinuation** but also exploring the factors contributing to **successful TFR**. Estimated loss of **MMR** was 16, 34, 39, and 41% at 3, 6, 12, and 24 months, respectively, for **patients** who **discontinued TKI treatment**.

Cited by: 8

Author: Kang-kang Chen, Tai-feng Du, Pei-sheng Xi...

Publish Year: 2019

Search Tools

Turn on Hover Translation (开启取词)

激活 Windows

转到“设置”以激活 Windows

Feedback

ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

32,300 Results

Any time ▾

Discontinuation of tyrosine kinase inhibitor therapy in ...

[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045\(18\)30192-X/fulltext](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30192-X/fulltext)

Tyrosine kinase inhibitors (TKIs) have improved the survival of **patients with chronic myeloid leukaemia**. Many **patients** have deep molecular responses, a **prerequisite** for **TKI therapy discontinuation**. We aimed to define precise conditions for **stopping treatment**.

Cited by: 175

Author: Susanne Saussele, Johan Richter, Joelle ...

Publish Year: 2018

Tyrosine kinase inhibitor discontinuation in patients with ...

<https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0686-1> ▾

Jan 03, 2019 · The introduction of imatinib, a selective **tyrosine kinase inhibitor** (TKI), revolutionized the treatment of **chronic myeloid leukemia** (CML) and changed the natural history of the disease [1, 2]. Subsequently, four additional TKIs were approved for the treatment of CML: bosutinib, dasatinib, nilotinib, and ponatinib.

Cited by: 18

Author: Kamal Chamoun, Hagop Kantarjian, Ram...

Publish Year: 2019

Tyrosine Kinase Inhibitor Therapy Discontinuation for ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6934633>

Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice Richard E. Clark Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Room 150, First floor, Sherrington Building, Ashton Street, Liverpool,, L69 3GE UK

Cited by: 5

Author: Richard E. Clark

Publish Year: 2019

Discontinuation of tyrosine kinase inhibitors in chronic ...

<https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.31411>

The ultimate goal of **chronic myeloid leukemia** management in the **tyrosine kinase inhibitor** (TKI) era for **patients** who obtain deep molecular responses is maintaining a durable off-treatment response after